UC Davis Health has opened enrollment in a trial testing whether an AI-assisted home pill dispenser called HiDO can help older adults with mild cognitive impairment to moderate dementia take their prescribed drugs on schedule, the university announced on October 7, 2026.
Picture the usual tool: a plastic organizer with the days of the week printed on the lid, a Tuesday slot still full by Wednesday night. It tells you a dose was missed, never whether a dose taken was actually swallowed. HiDO, made by HiDO Technologies, releases pre-loaded doses at scheduled times and records a short video meant to confirm the pill went down, then sends that record to a caregiver's phone through an app. That is the gap the device is built to close: not reminding, but confirming.
The trial, led by UC Davis neuropsychologists Alyssa Weakley and Sarah Tomaszewski Farias, will enroll 50 participants. Half will use the HiDO device with training and support; half will continue their usual medication routine. It is registered with the federal government as "Preventing Medication Mismanagement in People Living With Dementia" (NCT07600684), sponsored by HiDO Technologies under a National Institutes of Health small-business grant. The registry lists the study as actively recruiting since May 2026, with an estimated primary completion date of December 31, 2027, meaning no results are due for some time yet.
The device arrives with a track record, but an incomplete one. UC Davis researchers point to earlier feasibility work the company says found the dispenser practical, accurate, and easy to use for people with dementia and their caregivers. What that earlier work could not do is compare HiDO against ordinary care in a controlled trial. That comparison is the entire purpose of this study, and the reason families watching a loved one's medication routine should treat today's marketing claims as a question still being answered, not a settled fact.